{"id":107828,"title":"OKYO Pharma is scheduled to present data on their dry eye drug at an important conference.","publisher":"Share Talk","author":"sharetalk","published":"2023-05-03T06:29:57+00:00","modified":"2023-05-03T06:29:57+00:00","canonical_url":"https://www.share-talk.com/okyo-pharma-is-scheduled-to-present-data-on-their-dry-eye-drug-at-an-important-conference/","markdown_url":"https://www.share-talk.com/okyo-pharma-is-scheduled-to-present-data-on-their-dry-eye-drug-at-an-important-conference.md","json_url":"https://www.share-talk.com/okyo-pharma-is-scheduled-to-present-data-on-their-dry-eye-drug-at-an-important-conference.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["biotechnology","Bloomberg","diseases","Dr. Gary Jacob","Dr. Napoleone","dry eye","inflammatory","life sciences","NASDAQ","New York Medical College","OKYO","OKYO Pharma","Share Talk","Willy Simon"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO),** a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, California, from May 5-8.\n\nThe presentations will be delivered by Dr. Pedram Hamrah, a renowned expert on DED and corneal neuropathic pain, who serves as the co-director of the Cornea Service and director of the Center for Translational Ocular Immunology at the New England Eye Center at Tufts Medical Center.\n\nThe papers will focus on pre-clinical and animal model data, demonstrating the effectiveness of OK-101 in treating DED and Neuropathic Corneal Pain (NCP). OK-101 is a potential breakthrough treatment aimed at addressing the significant unmet need in the multi-billion-dollar market for DED."}